ScholarIQanswers from OpenAlex & ORCID
Daniel S. Chen
ResearcherPublications, citations & collaboration network
Daniel S. Chen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Daniel S. Chen have?
ScholarIQindexed works
Daniel S. Chen has 109 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Daniel S. Chen have?
ScholarIQcitation count
Daniel S. Chen has 47,247 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Daniel S. Chen?
ScholarIQh-index
Daniel S. Chen has an h-index of 39 in OpenAlex.
What is the i10-index of Daniel S. Chen?
ScholarIQi10-index
Daniel S. Chen has an i10-index of 58 in OpenAlex.
What is the ORCID of Daniel S. Chen?
ScholarIQorcid
The ORCID for Daniel S. Chen is on the source record.
What is the OpenAlex record for Daniel S. Chen?
ScholarIQopenalex
The OpenAlex for Daniel S. Chen is on the source record.
What are the most-cited papers on Daniel S. Chen?
ScholarIQmost cited works
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazières, Keunchil Park, David C. Smith, Á. Artal, C. Lewanski, Fadi Braiteh, Daniel Waterkamp, Pei He, Wei Zou, Daniel S. Chen, Jing Yi, Alan Sandler, Achim Rittmeyer
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
Marcin Kowanetz, Wei Zou, Scott Gettinger, Hartmut Koeppen, Mark Kockx, Peter Schmid, Edward E. Kadel, Ignacio I. Wistuba, Jamie E. Chaft, Naiyer A. Rizvi, David R. Spigel, Alexander I. Spira, Fred R. Hirsch, Victor Cohen, Dustin Smith, Zach Boyd, Natasha Miley, Susan Flynn, Vincent Lévêque, David S. Shames, Marcus Ballinger, Simonetta Mocci, Geetha Shankar, Roel Funke, Garret M. Hampton, Alan Sandler, Lukas C. Amler, Ira Mellman, Daniel S. Chen, Priti S. Hegde